SpaceX Mobile Network Could Cost Up to $130 Billion, Bernstein Says 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
OpenAI Nears Astra AI Model Launch With Safety Focus 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
MediaTek Shares Jump 10% on Nvidia’s $3.5 Billion Investment 
GSM Eyes US, Europe Expansion Ahead of 2028 Hong Kong IPO 
France Targets Shein, Temu With Fast-Fashion Fees 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
South Korea Unveils Record $597 Billion 2027 Budget to Boost AI and Chips 
Trump Secures Drug Pricing Deals With Nine Pharma Companies 
GM Canada Workers Approve C$1.1 Billion Investment Deal 
Lynas Rare Earths Shares Rise After Takeover Talks Revealed 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
CIA-Linked Investor Helped Quantum Systems Expand in US 
Add as a preferred source on Google
Call Scheduled for Monday, March 19, 2018 at 4:30pm Eastern Time.
NEW YORK, March 13, 2018 -- AIT Therapeutics Inc. (OTC:AITB), a clinical-stage biopharmaceutical company focused on developing inhaled Nitric Oxide (NO) for the treatment of patients with serious lung infections and pulmonary hypertension, will report financial results for the year ended December 31, 2017 and host a conference call and webcast at 4:30pm Eastern Time on Monday, March 19, 2018.
| Conference Call & Webcast | ||||||
| Monday, March 19th @ 4:30pm Eastern Time | ||||||
| Domestic: | 800-289-0438 | |||||
| International: | 323-994-2083 | |||||
| Passcode: | 1979356 | |||||
| Webcast: | http://public.viavid.com/index.php?id=128779 | |||||
| Replays available through April 2: | ||||||
| Domestic: | 844-512-2921 | |||||
| International: | 412-317-6671 | |||||
| Conference ID: | 1979356 | |||||
| | ||||||
About AIT Therapeutics Inc.
AIT Therapeutics Inc. is a clinical-stage biopharmaceutical company using nitric oxide (NO) to treat serious lung infections and pulmonary hypertension. The Company is currently applying its therapeutic expertise to treat lower respiratory tract infections that are not effectively addressed with current standards of care. AIT Therapeutics is advancing its revolutionary NO respiratory targeted system in clinical trials for the treatment of bronchiolitis and nontuberculous mycobacteria (NTM). For more information, visit www.AIT-Pharm.com.
CONTACT
Steven Lisi
Chief Executive Officer
AIT Therapeutics, Inc.
[email protected]
Bob Yedid
LifeSci Advisors, LLC
[email protected]
(646) 597 6989
